Black Diamond Therapeutics (NASDAQ:BDTX) used a presentation at the 46th annual TD Cowen Healthcare Conference to highlight ...
Mezigdomide (a CELMoD) combined with carfilzomib/dexamethasone met the phase 3 primary endpoint, delivering statistically ...
The randomized, double-blind, placebo-controlled, multicenter study enrolled 992 patients globally. The intent-to-treat ...
The Personal Financial Specialist (PFS) certification helps Certified Public Accountants (CPAs) demonstrate an expertise in all aspects of wealth management. A PFS is someone with a CPA who also ...
SAN FRANCISCO -- Frontline dual immunotherapy significantly improved progression-free survival (PFS) versus chemotherapy in microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) ...
Please provide your email address to receive an email when new articles are posted on . The addition of pyrotinib to trastuzumab and docetaxel improved 4-year OS vs. placebo for patients with ...
Patients with ER-positive, HER2-negative, ESR1-mutant advanced breast cancer experienced improvements in progression-free survival when being treated with Orserdu, study results showed. Findings from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results